CGD Policy Blogs
The Harvard Business School Journal Working Knowledge recently published an interview with Michael Kremer and Rachel Glennerster discussing "pull mechanisms" to encourage commercial vaccine R&D efforts for developing countries.
A new study published today in Nature (abstract here) suggests that there may have been as many as half a billion cases of Plasmodium falciparum across the world in 2002.
More than two-thirds of these occurred in Africa, where this more deadly form of malaria mostly affects children under-five. But far more cases than previously thought take place in SE Asia.
Because there are so many informed voices (and differing opinions) on issues relating to advance market commitments to vaccine development, we hope periodically to include brief interviews on this site -- and encourage readers to post follow-up comments and questions. If you have recommendations on appropriate candidates for interview, post a comment or feel free to send me an email..
There is a good article about vaccines in today's FT, which quotes the work that we have been doing:
The UK Government yesterday answered a written Parliamentary Question (a mechanism for formal statements of policy) on advance purchases of a malaria vaccine.
A group of researchers has published proposals for a new mechanism to improve collaboration and knowledge sharing on the development of medicines for tropical diseases.
In June 2004, at Sea Island, the G8 endorsed the Global HIV Vaccine Enterprise. This is a mechanism, first proposed in June 2003, which aims to enhance coordination, information sharing and global collaboration amongst the world's HIV vaccine researchers in industrialized and developing countries in both private and public sectors.